BRCA2 GENE MUTATION
Clinical trials for BRCA2 GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new BRCA2 GENE MUTATION trials appear
Sign up with your email to follow new studies for BRCA2 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug targets BRCA mutations beyond breast and ovarian
Disease control OngoingThis phase 2 trial tests the drug talazoparib in 150 people with advanced cancers that have not responded to standard treatments. Participants must have specific gene changes in BRCA1, BRCA2, or related DNA repair genes. The drug works by blocking an enzyme that helps cancer cell…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising prostate cancer trial for hispanic and black patients pulled before start
Disease control TerminatedThis was a phase 2 trial testing a combination of niraparib and abiraterone plus prednisone for metastatic hormone-sensitive prostate cancer in Hispanic/Latino and Black patients with specific gene mutations. The study aimed to enroll 64 people but was withdrawn before any partic…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: Qian Qin • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Keytruda takes on genetic weak spots in advanced tumors
Disease control OngoingThis phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy…
Matched conditions: BRCA2 GENE MUTATION
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Matched conditions: BRCA2 GENE MUTATION
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC
-
Genetic counseling by phone may ease cancer fears in High-Risk women
Knowledge-focused TerminatedThis study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…
Matched conditions: BRCA2 GENE MUTATION
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC